Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
前收盤價
US$88.48
+US$0.73 · +0.83%
盤中時間採用ET。市場資料可能有所延遲。
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
日內區間
目前US$88.48
52週區間
目前US$88.48
盤中時間採用ET。市場資料可能有所延遲。
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
日內區間
目前US$88.48
52週區間
目前US$88.48
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 363.64億 USD | 335.37億 USD | 323.64億 USD | 312.27億 USD | 316.86億 USD |
| 銷貨成本 | 127.21億 USD | 116.32億 USD | 112.16億 USD | 107.19億 USD | 101.45億 USD |
| 毛利 | 236.43億 USD | 219.05億 USD | 211.48億 USD | 205.08億 USD | 215.41億 USD |
| 研究與開發 | 28.73億 USD | 27.32億 USD | 27.35億 USD | 26.96億 USD | 27.46億 USD |
| 銷售、一般及管理費用 | 117.84億 USD | 108.49億 USD | 107.36億 USD | 104.15億 USD | 102.92億 USD |
| 營業費用 | 171.79億 USD | 159.5億 USD | 160.04億 USD | 150.23億 USD | 157.89億 USD |
| 利息支出 | 7.15億 USD | 7.29億 USD | 7.19億 USD | 6.36億 USD | 5.53億 USD |
| 折舊和攤銷 | 29.58億 USD | 28.61億 USD | 26.47億 USD | 26.97億 USD | 27.07億 USD |
| 營業利益 | 64.67億 USD | 59.55億 USD | 51.44億 USD | 54.85億 USD | 57.52億 USD |
| 淨利 | 48億 USD | 46.62億 USD | 36.76億 USD | 37.58億 USD | 50.39億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$97.80
上漲空間 10.53%年度分割調整後的每股現金分配。
US$2.83
2025年(完整年度)+14.6% 自從 2021
2026年(部分年度):US$2.15
US$2.47
2,021
US$2.67
2,022
US$2.75
2,023
US$2.79
2,024
US$2.83
2,025
US$2.15
2,026*
* 在現有股息歷史記錄中,該日曆年僅包含部分期間。
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年9月25日 | US$0.72Quarterly | 2026年9月25日 | 2026年10月16日 |
股息 | 2026年6月26日 | US$0.72Quarterly | 2026年6月26日 | 2026年7月17日 |
股息 | 2026年3月27日 | US$0.71Quarterly | 2026年3月27日 | 2026年4月17日 |
股息 | 2025年12月26日 | US$0.71Quarterly | 2025年12月26日 | 2026年1月16日 |
股息 | 2025年9月26日 | US$0.71Quarterly | 2025年9月26日 | 2025年10月17日 |
股息 | 2025年6月27日 | US$0.71Quarterly | 2025年6月27日 | 2025年7月11日 |
除息 2026年9月25日
US$0.72
Quarterly
2026年9月25日登記 · 支付日 2026年10月16日
除息 2026年6月26日
US$0.72
Quarterly
2026年6月26日登記 · 支付日 2026年7月17日
除息 2026年3月27日
US$0.71
Quarterly
2026年3月27日登記 · 支付日 2026年4月17日
除息 2025年12月26日
US$0.71
Quarterly
2025年12月26日登記 · 支付日 2026年1月16日
除息 2025年9月26日
US$0.71
Quarterly
2025年9月26日登記 · 支付日 2025年10月17日
除息 2025年6月27日
US$0.71
Quarterly
2025年6月27日登記 · 支付日 2025年7月11日
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T2168.47億0.17%129.43兆 JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI36.98億0.16%2.3兆 USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO30.92億0.18%1.8兆 USD0.03%US$715.59+0.61%
iShares Core S&P 500 ETFIVV14.93億0.17%8964.4億 USD0.03%US$781.97+0.60%
State Street SPDR S&P 500 ETFSPY13.7億0.17%8172億 USD0.09%US$778.57+0.60%
Vanguard Morningstar Value ETFVTV11.13億0.42%2624億 USD0.03%US$220.59+0.44%
State Street Health Care Select Sector SPDR ETFXLV8億1.84%435.37億 USD0.08%US$170.81+1.58%
Vanguard Dividend Appreciation ETFVIG6.59億0.50%1324億 USD0.04%US$239.05+0.70%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Value ETFVTV
State Street Health Care Select Sector SPDR ETFXLV
Vanguard Dividend Appreciation ETFVIGAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。